SCHEMBL25036744

SCHEMBL25036744

CCc1c(N2CCN(C(=O)OC(C)(C)C)CC2)c(=O)n2nc(N3CCCC3)nc2n1CC(=O)Nc1ccc(C(F)(F)F)nc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.43
▸ DPP4 P27487 1/20 0.36
▸ MAPT P10636 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ ESR2 Q92731 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ NR2F2 P24468 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ P2RX7 Q99572 2/20 0.32
▸ ACHE P22303 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ LOXL2 Q9Y4K0 1/20 0.32
▸ MAPK8 P45983 1/20 0.32
▸ GPR119 Q8TDV5 2/20 0.32
▸ DDB1 Q16531 1/20 0.32
▸ CRBN Q96SW2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30038368 1.00 WRN (0.43) WRNDPP4MAPTALDH1A1ESR2
SCHEMBL25037272 0.94 WRN (0.45) WRNDPP4MAPTALDH1A1ESR2
SCHEMBL30038970 0.93 WRN (0.40) WRNDPP4MAPTALDH1A1ESR2
SCHEMBL25037306 0.93 WRN (0.40) WRNDPP4MAPTALDH1A1ESR2
SCHEMBL30037354 0.91 WRN (0.43) WRNDPP4MAPTALDH1A1ESR2
SCHEMBL25037309 0.90 WRN (0.39) WRNDPP4MAPTALDH1A1ESR2
SCHEMBL30038802 0.89 WRN (0.42) WRNDPP4MAPTALDH1A1ESR2
SCHEMBL30038284 0.88 WRN (0.37) WRNP2RX3
SCHEMBL25035147 0.88 WRN (0.41) WRNSMN1; SMN2KMT2AP2RX3
SCHEMBL30037944 0.88 WRN (0.41) WRNSMN1; SMN2KMT2AP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046859-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046859-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 WRN 1829/4885DPP4 3644/4885MAPT 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback